Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?

Zargham, Mahtab; Abedi, Shideh; Alizadeh, Farshid; Khorami, Mohamad Hatef; Mohamadi, Mehrdad; Bahrami, Faranak; Sharifiaghdas, Farzaneh; Mazdak, Hamid

Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?

Document Type : Original Article

Authors

¹ Isfahan Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Urology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Intradetrusor injection of botulinum toxin A (BTX-A) might serve as a minimally invasive substitute in patients with refractory idiopathic overactive bladder (RIOAB). The aim of this study was to evaluate the clinical outcomes related to two different doses of abo-BTX-A (AboBTX-A) in patients with RIOAB. Materials and Methods: This prospective clinical trial was performed on 55 women with RIOAB. After determination of trabeculation grade, 300 (no or mild) or 500 (moderate or severe) unit of AboBTX-A (Dysport) was intravesicaly injected. Before 1, 3, and 6 months after intervention, lower urinary tract symptoms during 24 h were recorded. Results: Of the study population, 62% had severe bladder trabeculation. The mean duration of overactive bladder (OAB) was 1.76 versus 5.85 years, for no or mild versus severe trabeculation, respectively. After injections of 300- and 500-unit dosage, there were 19% and 26% early complications such as urinary retention. There was a statistically significant difference between the two groups in OAB score after 1 month (P < 0.001) and duration of OAB symptoms, over three follow-up times (P < 0.001). The mean preinjection OAB scores between patients with and without recurrence were statistically significant (29.36 vs. 25.07; P < 0.03). Urinary tract infection as a late complication was distinguished in four patients. Conclusion: In RIOAB, by adjusted dosage of AboBTX-A related to the grade of bladder trabeculation, in addition to maintain efficacy, consequent complications might not be affected by dosage and the drug dosage could be increased to nearly 60% with less concern associated to complication

Keywords

References

1.	Osman N, Mangera A, Hillary C, Inman R, Chapple C. The underactive bladder: Detection and diagnosis. F1000Res 2016;5. pii: F1000 Faculty Rev-102.
2.	Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
3.	McKillop C. Interview with Chris Chapple overactive bladder: Tackling the problem. Eur Urol 2006;49:921-3.
4.	Wein AJ, Rackley RR. Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J Urol 2006;175(3 Pt 2):S5-10.
5.	Vahdatpour B, Zargham M, Chatraei M, Bahrami F, Alizadeh F. Potential risk factors associated with stress urinary incontinence among Iranian women. Adv Biomed Res 2015;4:205. [PUBMED] [Full text]
6.	Zargham M, Alizadeh F, Moayednia A, Haghdani S, Nouri-Mahdavi K. The role of pelvic organs prolapse in the etiology of urinary incontinence in women. Adv Biomed Res 2013;2:22. [PUBMED] [Full text]
7.	Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001;358:401-3.
8.	Tyagi S, Thomas CA, Hayashi Y, Chancellor MB. The overactive bladder: Epidemiology and morbidity. Urol Clin North Am 2006;33:433-8.
9.	Cohen BL, Tunuguntla HS, Gousse A. Predictors of success for first stage neuromodulation: Motor versus sensory response. J Urol 2006;175:2178-80.
10.	Yeo EK, Hashim H, Abrams P. New therapies in the treatment of overactive bladder. Expert Opin Emerg Drugs 2013;18:319-37.
11.	Kizilyel S, Karakeçi A, Ozan T, Ünüs I, Barut O, Onur R. Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder. Turk J Urol 2015;41:208-14.
12.	National Collaborating Centre for Women's and Children's Health (UK). Urinary Incontinence in Women: The Management of Urinary Incontinence in Women. London: Royal College of Obstetricians and Gynaecologists (UK); 2013 September. National Institute for Health and Care Excellence: Clinical Guidelines; 2013.
13.	Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol 2013;29:2-11. [PUBMED] [Full text]
14.	Kim DK, Chancellor MB, Smith C, Thomas CA. The case for bladder botulinum toxin application. Urol Clin North Am 2006;33:503-10.
15.	Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919-22.
16.	Chapple C, Patel A. Botulinum toxin – New mechanisms, new therapeutic directions? Eur Urol 2006;49:606-8.
17.	Curcio L, Costa F, Marinho MA, Cunha AC, Renteria J, Dibiase Filho G. Use of botulinum toxin type A (Botox ^®) through transcystoscopicvesical insertion for overactive bladder syndrome non-responsive to oral medication or for parasympatholytic drugs use severe side effects. Braz J Video Sur 2008;1:97-103.
18.	Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164(3 Pt 1):692-7.
19.	Léon P, Jolly C, Binet A, Fiquet C, Vilette C, Lefebvre F, et al. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children. J Pediatr Surg 2014;49:1424-8.
20.	Morris AR, O'Sullivan R, Dunkley P, Moore KH. Extracorporeal magnetic stimulation is of limited clinical benefit to women with idiopathic detrusor overactivity: A randomized sham controlled trial. Eur Urol 2007;52:876-81.
21.	Mahdavi R, Sheikhi Z, Golshan A. Effect of botulinum neurotoxin type a injection in refractory idiopathic overactive bladder. J North Khorasan Univ Med Sci 2011;3:75-80.
22.	Truzzi J, Bruschini H, Simonetti R, Miguel S, editors. What is the Best Dose for Intravesical Botulinum-A Toxin Injection in Overactive Bladder Treatment? A Prospective Randomised Preliminary Study. Joint Meeting of the International Continence Society (ICS) and the International Uro-Gynaecological Association (IUGA), Paris, France; 2004.
23.	Werner M, Schmid DM, Schüssler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study. Am J Obstet Gynecol 2005;192:1735-40.
24.	Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type a and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006;49:528-35.
25.	Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005;96:848-52.
26.	Asplund R, Marnetoft SU, Selander J, Akerström B. Nocturia in relation to somatic health, mental health and pain in adult men and women. BJU Int 2005;95:816-9.
27.	Roux JW, Shah SS, Khan MS, Sahai A. Intradetrusor botulinum toxin injections for overactive bladder. Trends Urol Gynaecol Sex Health 2008;13:27-8.
28.	Elbadawi A. Voiding dysfunction in benign prostatic hyperplasia: Trends, controversies and recent revelations. II. Pathology and pathophysiology. Urology 1998;51 5A Suppl:73-82.
29.	Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22.
30.	Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22.
31.	Kennelly M, Schaecher KL. New treatments in overactive bladder and implications for managed care. J Manag Care Med 2006;9:35.
32.	Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: A randomised blinded placebo-controlled trial of 240 women (The RELAX study). Eur Urol 2012;62:507-14.
33.	McDougal WS, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, et al. Campbell-Walsh Urology. 10^th Edition Review. Philadelphia, Pennsylvania: Elsevier Health Sciences; 2011.
34.	Kajbafzadeh AM, Nikfarjam L, Mahboubi AH, Dianat S. Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia. Urology 2010;76:233-7.
35.	Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: Short-term effect on quality of life. Obstet Gynecol 2009;113:1046-51.
36.	Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007;100:1302-6.

Advanced Biomedical Research